



Noden Pharma DAC acquired by Stanley Capital

Dublin, 9th September 2020: Noden Pharma DAC (“Noden”), a global specialty pharmaceutical company, is pleased to announce it has been acquired in by Stanley Capital, the technology, healthcare, and sustainability-focused investment partnership. According to the terms of the agreement, the total value of the transaction will result in payments to PDL of up to \$52.83 million in cash. As part of this, Stanley Capital have replaced PDL BioPharma as the owners of the Noden Group.

The partnership with Stanley Capital will help Noden fulfil its ambition of consolidating the mature product speciality pharma marketplace by acquiring multiple drug portfolios to create a differentiated portfolio of medicines with established operational, technical, or patent-led barriers to entry. Stanley Capital will work alongside Noden’s management team to execute an identified and active pipeline of bolt -on acquisitions to help achieve this expansion of the company’s portfolio of essential drugs.

Alan Markey, Chief Executive Officer of Noden Pharma DAC, said: “We are delighted to partner with Stanley Capital and look forward to working together to realise our shared goal of building Noden into a leading global specialty pharmaceuticals company. As we start the next chapter in Noden’s growth story, I would like to thank our previous owners PDL BioPharma for all their support over the years and wish them the very best for the future.”

Simon Cottle, Partner at Stanley Capital, said: “The acquisition of Noden is the culmination of years of thematic research into the specialty pharmaceuticals sector, which identified the company as a strong buy and build platform. We look forward to working with Noden’s excellent management team and our industry advisors to build the company into a leading pharma platform, providing essential treatments for patients with unique and difficult to treat conditions.”

-ENDS-

Notes to Editors

About Noden Pharma DAC

Noden Pharma DAC is a global specialty pharmaceutical company that is focused on acquiring prescription medicines across a range of therapeutic areas. Noden Pharma DAC holds exclusive worldwide rights to manufacture, market and sell Tekturna® and Tekturna HCT® (or Rasilez® and Rasilez HTC® outside of the United States), which contain aliskiren, a direct renin inhibitor, for the treatment of hypertension. In March 2019, Noden announced the U.S commercial launch of an authorized generic form of Tekturna, aliskiren hemifumarate 150 mg and 300 mg tablets with the same drug formulation as Tekturna. Noden Pharma DAC is headquartered in Dublin, Ireland and Noden Pharma USA Inc. is incorporated in Delaware. For more information on Noden Pharma DAC please visit www.nodenpharma.com.



About Stanley Capital

Stanley Capital is a private equity partnership pursuing repeatable relative value and thematic investment strategies in technology, healthcare, and sustainability, targeting businesses with Enterprise Values of \$250mn to \$2.5bn.

Stanley Capital is focused on high-quality platform companies in resilient and growth subsectors, identified through deep sector research and operating networks, working with management teams to transform investments through enabling growth and market consolidation.

The partnership was founded in London in 2019 by Simon Cottle, James Brooks and Patrick Hargutt and is supported by a broad team of operating partners to assist with value creation execution.

<https://stanley-capital.com/>